Literature DB >> 28799842

Midterm Safety and Efficacy of Irreversible Electroporation of Malignant Liver Tumors Located Close to Major Portal or Hepatic Veins.

Martina Distelmaier1, Alexandra Barabasch1, Philipp Heil1, Nils A Kraemer1, Peter Isfort1, Sebastian Keil1, Christiane K Kuhl1, Philipp Bruners1.   

Abstract

Purpose To investigate the efficacy and safety of irreversible electroporation (IRE) in the treatment of hepatic tumors not suitable for thermal ablation (radiofrequency ablation [RFA] or microwave ablation). Materials and Methods This was an institutional review board-approved prospective study in 29 patients (15 men, 14 women; mean age, 63 years ± 12 [standard deviation]) with 43 primary (n = 8) or secondary (n = 35) malignant liver tumors who underwent computed tomography (CT)-guided IRE. All target tumors were located immediately adjacent to major hepatic veins, portal veins, or both; thus, they were not considered suitable for RFA or microwave ablation. Patients underwent postinterventional CT and magnetic resonance (MR) imaging. Systematic follow-up MR imaging was performed for 24 months on average to assess complete ablation, intrahepatic tumor recurrence, and complications. The 95% confidence intervals (CIs) were determined for the rate of bile duct strictures, incomplete ablation, and tumor recurrence. Results Complete ablation was achieved in 40 (93%; 95% CI: 85, 100) of 43 target tumors, with a safety margin of 5-10 mm, and was confirmed at immediate postinterventional CT and MR imaging. In 13 (33%; 95% CI: 18, 47) of 40 completely ablated tumors, intrahepatic tumor recurrence was observed at 2-18 months. However, only two (15%; 95% CI: 0, 35) of these 13 tumors were observed within the ablation zone. In the remaining 11 (85%; 95% CI: 65, 100), tumor growth was observed alongside the needle tract. None of the two true local recurrences occurred at the site of the vessel. All adjacent vessels remained perfused at follow-up. Five (24%; 95% CI: 5, 39) of 21 patients with target tumors adjacent to portal veins developed mild to moderate cholestasis 2-6 weeks after IRE. Conclusion IRE is useful to avoid incomplete ablation secondary to heat-sink effects and damage to major blood vessels; however, needle tract seeding is observed in 26% of treated tumors, and IRE induces sufficient local heating to bile ducts in 24% of ablations. © RSNA, 2017.

Entities:  

Mesh:

Year:  2017        PMID: 28799842     DOI: 10.1148/radiol.2017161561

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  30 in total

1.  Irreversible electroporation for hepatic tumors.

Authors:  Maurizio Pompili; Giampiero Francica
Journal:  J Ultrasound       Date:  2019-03-06

2.  Efficacy and safety of irreversible electroporation for malignant liver tumors: a systematic review and meta-analysis.

Authors:  Pankaj Gupta; Muniraju Maralakunte; Sathya Sagar; Praveen Kumar-M; Harish Bhujade; Sreedhara B Chaluvashetty; Naveen Kalra
Journal:  Eur Radiol       Date:  2021-02-27       Impact factor: 5.315

3.  Ultrasound-guided percutaneous irreversible electroporation of hepatic and abdominal tumors not eligible for surgery or thermal ablation: a western report on safety and efficacy.

Authors:  A Giorgio; F Amendola; A Calvanese; E Ingenito; B Santoro; P Gatti; E Ciracì; P Matteucci; V Giorgio
Journal:  J Ultrasound       Date:  2019-03-06

4.  Transcatheter intra-arterial perfusion (TRIP)-MRI biomarkers help detect immediate response to irreversible electroporation of rabbit VX2 liver tumor.

Authors:  Matteo Figini; Kang Zhou; Liang Pan; Chong Sun; Bin Wang; Su Hu; Jia Yang; Junjie Shangguan; Aydin Eresen; Yury Velichko; Vahid Yaghmai; Zhuoli Zhang
Journal:  Magn Reson Med       Date:  2019-12-18       Impact factor: 4.668

5.  Multidisciplinary management of liver metastases in patients with colorectal cancer: a consensus of SEOM, AEC, SEOR, SERVEI, and SEMNIM.

Authors:  R Vera; E González-Flores; C Rubio; J Urbano; M Valero Camps; J J Ciampi-Dopazo; J Orcajo Rincón; V Morillo Macías; M A Gomez Braco; G Suarez-Artacho
Journal:  Clin Transl Oncol       Date:  2019-07-29       Impact factor: 3.405

6.  Irreversible electroporation ablation of end-stage metastatic retroperitoneal lesions: Report on three cases and literature review.

Authors:  Tian'An Jiang; Qiyu Zhao; Guo Tian; Xinhua Chen; Liming Wu
Journal:  Exp Ther Med       Date:  2019-07-17       Impact factor: 2.447

7.  Irreversible electroporation of malignant liver tumors: Effect on laboratory values.

Authors:  Mohammed Alnaggar; Ammar M Qaid; Jibing Chen; Lizhi Niu; Kecheng Xu
Journal:  Oncol Lett       Date:  2018-07-02       Impact factor: 2.967

Review 8.  The evolution of interventional oncology in the 21st century.

Authors:  Thomas Helmberger
Journal:  Br J Radiol       Date:  2020-08-14       Impact factor: 3.039

9.  Simulated accuracy assessment of small footprint body-mounted probe alignment device for MRI-guided cryotherapy of abdominal lesions.

Authors:  Naoyuki Shono; Brian Ninni; Franklin King; Takahisa Kato; Junichi Tokuda; Takahiro Fujimoto; Kemal Tuncali; Nobuhiko Hata
Journal:  Med Phys       Date:  2020-03-28       Impact factor: 4.071

10.  Percutaneous Irreversible Electroporation for Treatment of Small Hepatocellular Carcinoma Invisible on Unenhanced CT: A Novel Combined Strategy with Prior Transarterial Tumor Marking.

Authors:  Feng Pan; Thuy D Do; Dominik F Vollherbst; Philippe L Pereira; Götz M Richter; Michael Faerber; Karl H Weiss; Arianeb Mehrabi; Hans U Kauczor; Christof M Sommer
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.